Daniel Von Hoff
Department of Pharmaceuticals
Horizon Discovery
Austria
Biography
Daniel is Physician in Chief, Senior Investigator, Director, Translational Research Division, Translational Genomics Research Institute (TGen) and a pioneer in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the early stages of the development of many of the anticancer agents that are now routinely used, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib and others. Daniel is leading the way in the areas of in vitro drug sensitivity testing and patient-stratified clinical trials to individualize treatment for cancer patients. He is Editor in Chief of the world renowned scientific Journal, Molecular Cancer Therapeutics, and has published over 542 papers, 133 book chapters, and 950 abstracts.
Research Interest
Clinical Research
